S'abonner

Advances in basic and clinical immunology in 2012 - 27/02/13

Doi : 10.1016/j.jaci.2013.01.012 
Javier Chinen, MD, PhD a, Luigi D. Notarangelo, MD b, William T. Shearer, MD, PhD a,
a Immunology, Allergy and Rheumatology Section, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, Houston, Tex 
b Departments of Pediatrics and Pathology, Harvard Medical School, Boston, Mass 

Corresponding author: William T. Shearer, MD, PhD, Allergy and Immunology, Texas Children's Hospital, 1102 Bates St, FC 330.01, Houston, TX 77030.

Abstract

Basic and clinical immunology articles published in the Journal in 2012 were mostly related to the expanding area of primary immunodeficiencies (PIDs). Novel forms of PID were identified by using whole-exome sequencing or after careful examination of flow cytometric data, as in the reports of lymphocyte-specific protein tyrosine kinase, CD27, and CD21 deficiencies. Absent IgG and IgA memory B cells were described in patients with hyper-IgE syndrome, which is consistent with defective antibody response and suggests a potential benefit of immunoglobulin replacement. Impaired production of antibodies to polysaccharide antigens by the human B-cell subset analog to murine B-1 cells was reported in a child with selective polysaccharide antibody deficiency. Increased production of inflammatory cytokines by monocyte-derived cells on Toll-like receptor activation was reported in patients with X-linked agammaglobulinemia, underscoring the important role of Bruton tyrosine kinase in modulation of inflammation. The mechanisms explaining susceptibility to yeast infections and development of chronic mucocutaneous candidiasis were extensively studied. Universal newborn screening for T-cell deficiencies is being implemented in several states, resulting in the diagnosis of a higher number of immunodeficient newborns than previously estimated. The use of laboratory testing to distinguish PIDs from HIV infection was clarified. In the management of PIDs, refinement of indication and strategies to hematopoietic stem cell transplantation resulted in improved outcomes. The use of anti–IL-6 mAbs showed promise as an alternative treatment in patients with Schnitzler syndrome.

Le texte complet de cet article est disponible en PDF.

Key words : Immunology, primary immunodeficiencies, chronic mucocutaneous candidiasis, IL-17, intravenous immunoglobulin, combined variable immunodeficiency, cell immunity, severe combined immunodeficiency, newborn screening

Abbreviations used : ADA, AIRE, BCR, CARD, CD, CD40L, CGD, CMC, CMV, CTL, CVID, HIES, HSCT, IVIG, KREC, LCK, LRBA, PID, SCID, STAT, SYK, TLR, TREC, Treg, VODI


Plan


 Supported by National Institutes of Health (NIH) grants RR0188, AI082978, AI036211, AI06944, and HD052102 and the David Fund of Texas Children’s Hospital.
 Disclosure of potential conflict of interest: L. D. Notarangelo is a Board member for the Immune Disease Institute; is employed by Children's Hospital Boston; has received one or more grants from or has one or more grants pending with the NIH, the Jeffrey Modell Foundation, and the Wiskott-Aldrich Foundation; and has received royalties from UpToDate. W. T. Shearer has been supported by one or more grants from the NIH (AI082978). J. Chinen declares that he has no relevant conflicts of interest.


© 2013  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 131 - N° 3

P. 675-682 - mars 2013 Retour au numéro
Article précédent Article précédent
  • Advances in environmental and occupational disorders in 2012
  • David B. Peden, Robert K. Bush
| Article suivant Article suivant
  • The Editors’ Choice
  • Donald Y.M. Leung, Stanley J. Szefler, Associate Editors of the JACI

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.